Mikihisa Takano
Overview
Explore the profile of Mikihisa Takano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akai M, Maeda Y, Kawami M, Yumoto R, Takano M, Uchida Y
Biochim Biophys Acta Gen Subj
. 2024 Dec;
1869(2):130746.
PMID: 39706375
MicroRNAs (miRNAs), which are small non-coding RNAs, are recognized as important significant endogenous bio-molecules that regulate the post-transcriptional processes of target genes. However, predictive methods for significantly working miRNAs are...
2.
Yoshimori T, Kawami M, Kumagai Y, Futatsugi S, Yumoto R, Uchida Y, et al.
Int J Biochem Cell Biol
. 2024 May;
172:106601.
PMID: 38821314
Abemaciclib (ABM), a cyclin-dependent kinase 4/6 inhibitor, shows pharmacological effects in cell cycle arrest. Epithelial-mesenchymal transition is an important cellular event associated with pathophysiological states such as organ fibrosis and...
3.
Kawami M, Ojima T, Yumoto R, Takano M
Toxicol Res
. 2022 Oct;
38(4):449-458.
PMID: 36277370
Methotrexate (MTX) is widely used to treat various diseases. However, it induces adverse reactions like serious lung injury, including pulmonary fibrosis. Increasing evidence suggests that epithelial-mesenchymal transition (EMT) in injured...
4.
Ogiso H, Suno R, Kobayashi T, Kawami M, Takano M, Ogasawara M
Molecules
. 2022 Aug;
27(15).
PMID: 35956840
Molecular interaction analysis is an essential technique for the study of biomolecular functions and the development of new drugs. Most current methods generally require manipulation to immobilize or label molecules,...
5.
Kawami M, Honda M, Hara T, Yumoto R, Takano M
Biol Pharm Bull
. 2022 Jul;
45(8):1069-1076.
PMID: 35908888
Methotrexate (MTX) is known to induce serious lung diseases, such as pulmonary fibrosis. Although we demonstrated that MTX is associated with epithelial-mesenchymal transition (EMT), the underlying mechanism remains unclear. Nuclear...
6.
Takano M, Kuriyama S, Kameda N, Kawami M, Yumoto R
Biol Pharm Bull
. 2022 Feb;
45(2):213-219.
PMID: 35110509
In the lung alveolar region, the innate immune system serves as an important host defense system. We recently reported that peptide transporter 2 (PEPT2) has an essential role in the...
7.
Kawami M, Takenaka S, Akai M, Yumoto R, Takano M
Biomolecules
. 2021 Dec;
11(12).
PMID: 34944497
Background: Epithelial-mesenchymal transition (EMT), a phenotypic conversion of the epithelial to mesenchymal state, contributes to cancer progression. Currently, several microRNAs (miRNAs) are associated with EMT-mediated cancer progression, but the contribution...
8.
Katagiri Y, Kawaguchi H, Umemura K, Tadano J, Miyawaki I, Takano M
Drug Metab Pharmacokinet
. 2021 Dec;
42:100430.
PMID: 34896751
Breast cancer resistance protein (BCRP) expressed in the blood-brain barrier plays a major role in limiting drug distribution into the central nervous system (CNS). However, functional involvement of BCRP in...
9.
Kawami M, Takenaka S, Kadekaru Y, Akai M, Konaka T, Yumoto R, et al.
Toxicology
. 2021 Aug;
461:152903.
PMID: 34425168
Several studies using bleomycin (BLM)-induced lung injury rat model revealed that epithelial-mesenchymal transition (EMT) contributes to pulmonary fibrosis. Conversely, microRNAs (miRNAs) are considered as useful markers of various diseases. In...
10.
Ojima T, Kawami M, Yumoto R, Takano M
Toxicol Res
. 2021 Jul;
37(3):293-300.
PMID: 34295794
Epithelial-mesenchymal transition (EMT), a biological process through which epithelial cells transdifferentiate into mesenchymal cells, is involved in several pathological events, such as cancer progression and organ fibrosis. So far, we...